Navigation Links
Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry
Date:9/2/2007

a from other TAXUS clinical trials and registries, offering further evidence that the TAXUS Liberte stent system continues to show positive safety outcomes in real-world use."

"The one-year OLYMPIA data show excellent outcomes with the TAXUS Liberte stent system across a large patient population with a broad range of lesion complexity, including diabetics who have typically demonstrated increased event rates," said Jeff Goodman, President of Boston Scientific International. "Our second-generation stent platform - TAXUS Liberte - offers exceptional deliverability and is the only current drug-eluting stent geometry designed specifically for drug elution. The strong clinical results, excellent performance in diabetics and solid physician preference have allowed TAXUS Liberte to take a clear leadership role in European and Intercontinental markets."

The global, prospective OLYMPIA registry is the world's largest DES registry and plans to enroll up to 26,000 patients from more than 400 centers worldwide. OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS Liberte paclitaxel-eluting stent system in the treatment of patients with coronary artery disease.

The OLYMPIA European and Intercontinental launch phases consisted of diverse and high-risk patient populations, reflecting complex usage patterns in "real-world" clinical practices. A majority of patients exhibited complex lesions or clinical characteristics, including, multi-vessel disease (57.7 percent), prior myocardial infarction (MI) (37.3 percent), acute MI (17.8 percent), multiple stents (32.9 percent), type B2/C lesions (56.6 percent) and diabetes (33.4 percent). Of the first 7,124 patients enrolled, 92.5 percent (6,593 patients) were available for evaluation at one year.

Patients with a single vessel treated with only one TAXUS Liberte stent were considered simple use patients and comprised 27.6 percent of the total. Complex use p
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Funds will support public safety communications interoperabilty
3. High interest forces delay in food safety symposium
4. Human factors and IT: Designing for patient safety
5. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
6. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
7. Thompson receives leadership award for technology solutions for patient safety
8. Thermal Cycling Profile for Standard PCR
9. PCR Polymerases Application Profiles
10. Setting up a kinase profiler with IMAP
11. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Altadena, CA (PRWEB) January 14, 2014 ... Angeles County), California, and Montreal, Canada, has big ideas ... and non-fiction. The press's goals are to produce high-quality, ... e-books to support local businesses. , The first ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... The review process being used by the Food and Drug ... fails to weigh the full effects of the fish,s widespread ... this week,s Science . The salmon, whose genome ... the first genetically modified animal approved for human consumption in ...
... FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... Piper Jaffray Health Care Conference on Tuesday, November 30, ...
... Patients with Relapsed or Refractory Solid Tumors ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:FDA review on transgenic salmon too narrow 2FDA review on transgenic salmon too narrow 3HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10
(Date:4/23/2014)... million Food Standards Agency (FSA) project to map the ... , Norovirus outbreaks can rapidly affect large numbers ... strawberries infected 11,000 people in Germany, but there are ... cause infection and which foods are the most likely ... produce data that will help the FSA to develop ...
(Date:4/22/2014)... Coral Gables, Fla. (April 21, 2014) -- There are ... out their feathers and spread their colorful tails; satin ... them with blue and shiny objects; and European bitterling ... Each species has evolved a unique method to communicate ... "Signaling can have profound fitness ...
(Date:4/22/2014)... FL, April 22, 2014 Scientists from the Florida ... a protein complex that plays a critical but previously ... The study, which showed a novel role for a ... in the journal eLife , a publisher supported ... Society and the Wellcome Trust. , "This is a ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3Scientists identify critical new protein complex involved in learning and memory 2
... that it will launch a major long-term project to ... The project is made possible by a $10 million ... of Los Angeles-based Tennenbaum Capital Partners and philanthropist. The ... the ocean,s coastal ecosystems over a long period of ...
... University of Illinois cell and developmental Biology professor Fei ... study how myeloids, a type of blood stem cell, ... defense against infections and tissue damage. This approach offers ... myeloid differentiation, and may improve our ability to treat ...
... DCOctober 25, 2012Biomedical and health research and development (R&D) ... billion or 3% between FY10 and FY11 according to ... represents the first drop in overall spending since Research!America ... follows an uptick in research funding attributed to the ...
Cached Biology News:Smithsonian launches global marine biodiversity project with $10 million donation 2Smithsonian launches global marine biodiversity project with $10 million donation 3A new technique to study how myeloids become white blood cells 2US investment in biomedical and health research on downward trend 2
Quartz-Halogen, 100 W, High Intensity...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
...
Biology Products: